HOW TO MANAGE PATIENTS WITH LOW RESPONSE TO CLOPIDOGREL Clopidogrel dosage The Intracoronary Stenting and Antithrombotic Regimen : Choose Between 3 High Oral Doses

1 Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington DC, USA; 2 Département de Cardiologie, Hopital Universitaire Nord de Marseille, Marseille, France; 3 Laboratoire d’Hématologie, Unite Inserm UMRS 608, UFR de Pharmacie, Hopital de la Conception, Marseille, France; 4 Service de Cardiologie B et Centre Hémodynamique, Hopital Cardiologique, Centre Hospitalier Regional et Universitaire de Lille, Lille, France; 5 Département de Cardiologie, Clinique les fleurs, Ollioules, France

[1]  S. Yuan,et al.  Accessory Mitral Valve Tissue: A Case Report and an Updated Review of Literature , 2008, Journal of cardiac surgery.

[2]  Matthew J Price,et al.  Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.

[3]  J. Tardif,et al.  Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. , 2008, Journal of the American College of Cardiology.

[4]  R. Blindt,et al.  The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis , 2007, Thrombosis and Haemostasis.

[5]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[6]  P. Morange,et al.  ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome , 2007, Thrombosis and Haemostasis.

[7]  A. Gori,et al.  Different methodologies for evaluating the effect of clopidogrel on platelet function in high‐risk coronary artery disease patients , 2007, Journal of thrombosis and haemostasis : JTH.

[8]  P. Auquier,et al.  Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events , 2007, Journal of thrombosis and haemostasis : JTH.

[9]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[10]  M. Gawaz,et al.  Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease , 2007, Heart.

[11]  P. Gurbel,et al.  Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? , 2007, Journal of the American College of Cardiology.

[12]  P. Morange,et al.  Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. , 2006, Journal of the American College of Cardiology.

[13]  P. Sandset,et al.  Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.

[14]  W. Weaver,et al.  Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. , 2006, American heart journal.

[15]  P. Gurbel,et al.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. , 2005, Journal of the American College of Cardiology.

[16]  P. Gurbel,et al.  Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.

[17]  A. Kastrati,et al.  Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.

[18]  P. Théroux,et al.  Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. , 2005, Journal of the American College of Cardiology.

[19]  W. Herzog,et al.  The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. , 2005, Journal of the American College of Cardiology.

[20]  V. Pasceri,et al.  Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.

[21]  R. Wilcox,et al.  Clopidogrel resistance , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[22]  U. Walter,et al.  CORONARY ARTERY DISEASE Original Studies Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation , 2003 .

[23]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[24]  P. Järemo,et al.  Individual variations of platelet inhibition after loading doses of clopidogrel , 2002, Journal of internal medicine.

[25]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[26]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[27]  J. Moses,et al.  Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. , 1999, Circulation.

[28]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[29]  Julio C. Palmaz,et al.  Clinical Experience With the Palmaz‐Schatz Coronary Stent: Initial Results of a Multicenter Study , 1991, Circulation.

[30]  O. Morel,et al.  [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. , 2007, Annales de cardiologie et d'angeiologie.

[31]  P. Gurbel,et al.  The difference between clopidogrel responsiveness and posttreatment platelet reactivity. , 2005, Thrombosis research.